Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells

Leukemia

Volumn 19, Issue 1, 2005, Pages 64-68

  Molina Arcas, M ^a   Marce S ^b   Villamor, N ^b   Huber Ruano, I ^a   Casado, F J ^a   Bellosillo, B ^b,c   Montserrat, E ^b   Gill, J ^a   Colomer, D ^b   Pastor Anglada, M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL DEL MAR   (Spain)

Author keywords

Chronic lymphocytic leukemia; Fludarabine; Nucleoside transporters

Indexed keywords

FLUDARABINE; NUCLEOSIDE TRANSPORTER; NUCLEOSIDE TRANSPORTER 2; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG RESPONSE; DRUG SENSITIVITY; DRUG UPTAKE; EX VIVO STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; WESTERN BLOTTING;

EID: 19944427083     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403582     Document Type: Article

References (31)

1. Kipps TJ. Immunobiology of chronic lymphocytic leukemia. Curr Opin Hematol 2003; 10: 312-318.
2. Reed JC. Molecular biology of chronic lymphocytic leukemia. Semin Oncol 1998; 25: 11-18.
3. Robak T, Kasznicki M. Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia. Leukemia 2002; 16: 1015-1027.
4. Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E, Gil J. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood 1999; 94: 2836-2843.
5. Carrera CJ, Piro LD, Saven A, Beutler E, Terai C, Carson DA. 2-Chlorodeoxyadenosine chemotherapy triggers programmed cell death in normal and malignant lymphocytes. Adv Exp Med Biol 1991; 309A 15-18.
6. Carson DA, Wasson DB, Esparza LM, Carrera CJ, Kipps TJ, Cottam HB. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine. Proc Natl Acad Sci USA 1992; 89: 2970-2974.
7. Reed JC, Kitada S, Kim Y, Byrd J. Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiers. Semin Oncol 2002; 29: 10-24.
8. Robertson LE, Chubb S, Meyn RE, Story M, Ford R, Hittelman WN et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine. Blood 1993; 81: 143-150.
9. Zinzani PL, Tosi P, Visani G, Martinelli G, Farabegoli P, Buzzi M et al. Apoptosis induction with three nucleoside analogs on freshly isolated B-chronic lymphocytic leukemia cells. Am J Hematol 1994; 47: 301-306.
10. Genini D, Adachi S, Chao Q, Rose DW, Carrera CJ, Cottam HB et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000; 96: 3537-3543.
11. Sturm I, Bosanquet AG, Hermann S, Guner D, Dorken B, Daniel PT. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ 2003; 10: 477-484.
12. Dumontet C, Fabianowska-Majewska K, Mantincic D, Callet BE, Tigaud I, Gandhi V et al. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol 1999; 106: 78-85.
13. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 2001; 15: 875-890.
14. Galmarini CM, Jordheim L, Dumontet C. Role of IMP-selective 5′-nucleotidase (cN-II) in hematological malignancies. Leuk Lymphoma 2003; 44: 1105-1111.
15. Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch 2004; 447: 735-743.
16. Gray JH, Owen RP, Giacomini KM. The concentrative nucleoside transporter family, SLC28. Pflugers Arch 2004; 447: 728-734.
17. Pastor-Anglada M, Molina-Arcas M, Casado FJ, Bellosillo B, Colomer D, Gil J. Nucleoside transporters in chronic lymphocytic leukaemia. Leukemia 2004; 18: 385-393.
18. Molina-Arcas M, Bellosillo B, Casado FJ, Montserrat E, Gil J, Colomer D et al. Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia. Blood 2003; 101: 2328-2334.
19. Farre X, Guillen-Gomez E, Sanchez L, Hardisson D, Plaza Y, Lloberas J et al. Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors. Int J Cancer 2004; 112: 959-966.
20. Mackey JR, Jennings LL, Clarke ML, Santos CL, Dabbagh L, Vsianska M et al. Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. Clin Cancer Res 2002; 8: 110-116.
21. Galmarini CM, Thomas X, Calvo F, Rousselot P, Rabilloud M, El Jaffari A et al. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br J Haematol 2002; 117: 860-868.
22. Jaffe ES, Harris NL, Stein H, Vardiman JW (ed). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, 2001, IARC Press: Lyon, 168-170.
23. Colomer D, Vives Corrons JL, Bartrons R. Effect of TPA on fructose 2,6-bisphosphate levels and protein kinase C activity in B-chronic lymphocytic leukemia (B-CLL). Biochim Biophys Acta 1991; 1097: 270-274.
24. Valdes R, Ortega MA, Casado FJ, Felipe A, Gil A, Sanchez-Pozo A et al. Nutritional regulation of nucleoside transporter expression in rat small intestine. Gastroenterology 2000; 119 1623-1630.
25. Alessi-Severini S, Gati WP, Belch AR, Paterson AR. Intracellular pharmacokinetics of 2-chlorodeoxyadenosine in leukemia cells from patients with chronic lymphocytic leukemia. Leukemia 1995; 9: 1674-1679.
26. Wright AM, Gati WP, Paterson AR. Enhancement of retention and cytotoxicity of 2-chlorodeoxyadenosine in cultured human leukemic lymphoblasts by nitrobenzylthioinosine, an inhibitor of equilibrative nucleoside transport. Leukemia 2000; 14: 52-60.
27. Campas C, Lopez JM, Santidrian AF, Barragan M, Bellosillo B, Colomer D, Gil J. Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes. Blood 2003; 101: 3674-3680.
28. Gati WP, Paterson AR, Larratt LM, Turner AR, Belch AR. Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein. Blood 1997; 90: 346-353.
29. Aguayo C, Casado FJ, Pastor-Anglada M, Sobrevia L. Effect of hyperglycaemia on cellular localization of human equilibrative nucleoside transporters (hENT) in umbilical vein endothelial cells. J Physiol 2001, 536p.
30. Lai Y, Tse CM, Unadkat JD. Mitochondrial expression of the human equilibrative nucleoside transporter 1 (hENT1) results in enhanced mitochondrial toxicity of antiviral drugs. J Biol Chem 2004; 279 4490-4497.
31. Coe I, Zhang Y, McKenzie T, Naydenova Z. PKC regulation of the human equilibrative nucleoside transporter, hENT1. FEBS Lett 2002; 517: 201-205.